Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "IDA"

1936 News Found

GMM Pfaudler posts Q3 FY24 consolidated PAT at Rs. 31.72 Cr
News | February 03, 2024

GMM Pfaudler posts Q3 FY24 consolidated PAT at Rs. 31.72 Cr

GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023


Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr
News | February 02, 2024

Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr

Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023


Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr
News | February 02, 2024

Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr

Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023


Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr
News | February 02, 2024

Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr

Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023


Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr
News | February 02, 2024

Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr

Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023


Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr
News | February 01, 2024

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023


EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer
Drug Approval | January 29, 2024

EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer

Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival


Astec LifeSciences posts Q3 FY24 consolidated loss at Rs. 24.33 Cr
News | January 26, 2024

Astec LifeSciences posts Q3 FY24 consolidated loss at Rs. 24.33 Cr

Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023


Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr
News | January 25, 2024

Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr

Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023


Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
News | January 25, 2024

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023